Quest Diagnostics Q1 2025 Earnings Report Highlights Revenue Growth and Regulatory Developments
Quest Diagnostics (DGX) reported 12% revenue growth in Q1 2025, driven by organic demand, acquisitions, and advanced diagnostics. The company reaffirmed its full-year guidance and discussed the impact of a court ruling that overturned an FDA regulation on lab-developed tests. The decision is expected to reduce regulatory burdens and maintain access to innovative testing services.
Tickers: $DGX
Topics: acquisitions AI and automation earnings FDA regulation revenue growth